Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma
Molecular testing predicts which aggressive lymphoma patients benefit from a specific targeted drug, enabling precision treatment.
This retrospective study evaluates clinical outcomes of BTK inhibitor treatment in the MCD molecular subtype of DLBCL, a biologically aggressive variant uniquely dependent on BCR/NF-kB signaling due to MYD88 and CD79B co-mutations. LymphGen molecular classification provided differential predictive value for BTK inhibitor response, supporting precision treatment approaches in refractory DLBCL.
What the study was
- Study design
- Retrospective cohort study
- Population
- Adult DLBCL patients with MCD molecular subtype (MYD88/CD79B co-mutation)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Hematological oncology
Why it surfaced
MCD DLBCL is a high-unmet-need molecular subtype; BTK inhibitor precision evidence expands treatment options in a biologically distinct DLBCL subgroup.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.